Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C

Human Pathology

Volumn 32, Issue 9, 2001, Pages 904-909

  Fontaine, Hélène ^a   Nalpas, Bertrand ^a   Poulet, Bruno ^a   Carnot, Françoise ^a   Zylberberg, Hervé ^a   Brechot, Christian ^a   Pol, Stanislas ^b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b INSERM   (France)

Author keywords

Hepatitis C virus; Knodell score; Liver fibrosis; Metavir score

Indexed keywords

ADULT; ARTICLE; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE;

EID: 0034802790     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1053/hupa.2001.28228     Document Type: Article

References (33)

1. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis
2. Long term clinical and histopathological follow up of chronic post transfusion hepatitis
3. Long-term mortality after transfusion associated non-A, non-B hepatitis. The national heart, lung, and blood institute study group
4. Clinical outcomes after transfusion associated hepatitis C
5. Natural history of liver fibrosis progression in patients with chronic hepatitis C
6. Epidemiological factors affecting the severity of hepatitis C vires-related liver disease: A French survey of 6,664 patients
7. Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: A comparison between immunocompetent and immunocompromised patients
8. Hepatitis C virus type 1b (II) infection in France and Italy
9. The natural history of community acquired hepatitis C in United States
10. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
11. Interferon in nonA-nonB hepatitis: A meta-analysis of randomised clinical trials
12. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C
13. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C
14. Randomised trial of interferon α 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
15. Development of a simple restriction fragment length polymorphism (RFLP) based assay for HCV genotyping and comparative analysis with genotyping and serotyping tests
16. Formulation application of a numerical system for assessing histological activity in asa asymptomatic chronic active hepatitis
17. An algorithm for the grading of activity in chronic hepatitis C
18. Epidemiology and long-term prognosis of hepatitis C virus infection in Japan
19. Long-term follow-up of chronic post-transfusion non-A, non-B hepatitis: Clinical and histological outcome
20. The natural course of chronic hepatitis C: A comparison between patients with genotypes 1 and 2 hepatitis C viruses
21. HCV genotypes in Northern Italy: A survey of 1368 histologically proven chronic hepatitis C patients
22. Clinical significance of concomitant hepatitis C infection in patients with alcoholic liver disease
23. The importance of co-factors in the histologic progression of minimal and mild chronic hepatitis C
24. Prevalence of hepatitis C virus genotypes in Italy
25. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A case-control study
26. Different genotypes of hepatitis C virus are associated with different severity of chronic liver disease
27. Hepatitis C virus genotypes are not responsible for development of serious liver diseases
28. Hepatitis C virus genotypes and development of hepatocellular carcinoma
29. Genotypes in the progression of hepatitis C related cirrhosis and development of hepatocellular carcinoma
30. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation
31. Long-term outcome of hepatitis C infection after liver transplantation
32. Recurrent and acquired hepatitis C viral infection in liver transplant recipients
33. Changes in liver fibrosis at the end of alpha interferon therapy and 6 to 18 months later in patients with chronic hepatitis C: Quantitative assessment by a morphometric method